Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 17/20 | 0.62 |
| ▸ | TACR1 | P25103 | 6/20 | 0.62 |
| ▸ | TACR3 | P29371 | 5/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL758094 | 0.92 | TACR2 (0.63) | TACR2TACR1TACR3 | |
| SCHEMBL755410 | 0.91 | TACR2 (0.63) | TACR2TACR1TACR3 | |
| SCHEMBL755080 | 0.90 | TACR2 (0.67) | TACR2TACR1TACR3 | |
| SCHEMBL756998 | 0.89 | TACR2 (0.63) | TACR2TACR1TACR3 | |
| SCHEMBL756543 | 0.89 | TACR2 (0.63) | TACR2TACR1TACR3 | |
| SCHEMBL755411 | 0.88 | TACR2 (0.63) | TACR2TACR1TACR3 | |
| SCHEMBL756139 | 0.87 | TACR2 (0.63) | TACR2TACR1TACR3 | |
| SCHEMBL755870 | 0.87 | TACR2 (0.63) | TACR2TACR1TACR3 | |
| SCHEMBL756104 | 0.86 | TACR2 (0.61) | TACR2TACR1TACR3 | |
| SCHEMBL755437 | 0.86 | TACR2 (0.61) | TACR2TACR1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118093-B1 | [1,2,3]TRIAZOLYL SUBSTITUTED QUINOLINES AND COUMARINS AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK CANADA INC (CA) | 2012-03-21 | — | — | EP | claimed |
| EP-1954678-B1 | NOVEL NK1 AND NK2 ANTAGONISTS | ABBOTT PRODUCTS GMBH (DE) | 2012-03-21 | — | — | EP | claimed |
| US-7592344-B2 | NK1 and NK2-antagonists and compositions and methods of using the same | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-09-22 | — | — | US | claimed |
| US-20070149537-A1 | NK1 and NK2-antagonists and compositions and methods of using the same | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-06-28 | — | — | US | claimed |
| EP-1954678-B1 | NOVEL NK1 AND NK2 ANTAGONISTS | ABBOTT PRODUCTS GMBH (DE) | 2012-03-21 | — | — | EP | disclosed |
| US-7592344-B2 | NK1 and NK2-antagonists and compositions and methods of using the same | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-20070149537-A1 | NK1 and NK2-antagonists and compositions and methods of using the same | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149537-A1 | NK1 and NK2-antagonists and compositions and methods of using the same | HRH2, PROKR2, BDKRB2 | TACR2 7/4885TACR1 9/4885TACR3 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.